nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylergometrine—CYP3A4—Temozolomide—brain cancer	0.156	0.487	CbGbCtD
Methylergometrine—CYP3A4—Lomustine—brain cancer	0.133	0.414	CbGbCtD
Methylergometrine—HTR1F—trigeminal nerve—brain cancer	0.0812	0.153	CbGeAlD
Methylergometrine—HTR2C—choroid plexus—brain cancer	0.0631	0.119	CbGeAlD
Methylergometrine—CYP3A4—Etoposide—brain cancer	0.0321	0.1	CbGbCtD
Methylergometrine—HTR2A—choroid plexus—brain cancer	0.0316	0.0595	CbGeAlD
Methylergometrine—HTR1F—ganglion—brain cancer	0.0293	0.0551	CbGeAlD
Methylergometrine—DRD1—telencephalic ventricle—brain cancer	0.0238	0.0447	CbGeAlD
Methylergometrine—HTR2C—telencephalic ventricle—brain cancer	0.0185	0.0347	CbGeAlD
Methylergometrine—HTR2A—trigeminal nerve—brain cancer	0.016	0.0301	CbGeAlD
Methylergometrine—HTR2A—cerebellar cortex—brain cancer	0.0159	0.03	CbGeAlD
Methylergometrine—DRD1—ganglion—brain cancer	0.0148	0.0278	CbGeAlD
Methylergometrine—HTR2A—vein—brain cancer	0.0145	0.0272	CbGeAlD
Methylergometrine—HTR2C—ganglion—brain cancer	0.0115	0.0216	CbGeAlD
Methylergometrine—HTR2A—cranial nerve—brain cancer	0.0114	0.0214	CbGeAlD
Methylergometrine—HTR1F—telencephalon—brain cancer	0.0113	0.0212	CbGeAlD
Methylergometrine—HTR2A—pons—brain cancer	0.0113	0.0212	CbGeAlD
Methylergometrine—HTR1E—brainstem—brain cancer	0.011	0.0207	CbGeAlD
Methylergometrine—Vasospasm—Carmustine—brain cancer	0.011	0.0771	CcSEcCtD
Methylergometrine—HTR1E—telencephalon—brain cancer	0.00978	0.0184	CbGeAlD
Methylergometrine—HTR2A—telencephalic ventricle—brain cancer	0.00927	0.0174	CbGeAlD
Methylergometrine—HTR2A—pineal body—brain cancer	0.00804	0.0151	CbGeAlD
Methylergometrine—HTR1F—head—brain cancer	0.00703	0.0132	CbGeAlD
Methylergometrine—DRD1—brainstem—brain cancer	0.00643	0.0121	CbGeAlD
Methylergometrine—HTR1F—central nervous system—brain cancer	0.00642	0.0121	CbGeAlD
Methylergometrine—HTR1E—head—brain cancer	0.00609	0.0115	CbGeAlD
Methylergometrine—HTR2A—ganglion—brain cancer	0.00577	0.0108	CbGeAlD
Methylergometrine—DRD1—telencephalon—brain cancer	0.00571	0.0107	CbGeAlD
Methylergometrine—HTR1E—central nervous system—brain cancer	0.00556	0.0105	CbGeAlD
Methylergometrine—HTR1F—brain—brain cancer	0.0051	0.00958	CbGeAlD
Methylergometrine—HTR2C—brainstem—brain cancer	0.005	0.0094	CbGeAlD
Methylergometrine—HTR2A—endothelium—brain cancer	0.00497	0.00936	CbGeAlD
Methylergometrine—HTR2A—blood vessel—brain cancer	0.00459	0.00863	CbGeAlD
Methylergometrine—HTR2C—telencephalon—brain cancer	0.00444	0.00834	CbGeAlD
Methylergometrine—HTR1E—brain—brain cancer	0.00441	0.0083	CbGeAlD
Methylergometrine—HTR2A—hindbrain—brain cancer	0.00437	0.00823	CbGeAlD
Methylergometrine—HTR2B—telencephalon—brain cancer	0.00417	0.00784	CbGeAlD
Methylergometrine—DRD1—midbrain—brain cancer	0.0041	0.00771	CbGeAlD
Methylergometrine—Sweating increased—Procarbazine—brain cancer	0.00367	0.0257	CcSEcCtD
Methylergometrine—Angina pectoris—Procarbazine—brain cancer	0.00367	0.0257	CcSEcCtD
Methylergometrine—DRD1—head—brain cancer	0.00356	0.00669	CbGeAlD
Methylergometrine—HTR2C—medulla oblongata—brain cancer	0.00349	0.00656	CbGeAlD
Methylergometrine—DRD1—central nervous system—brain cancer	0.00325	0.0061	CbGeAlD
Methylergometrine—Haematuria—Procarbazine—brain cancer	0.0032	0.0225	CcSEcCtD
Methylergometrine—HTR2C—midbrain—brain cancer	0.00319	0.00599	CbGeAlD
Methylergometrine—Thrombophlebitis—Carmustine—brain cancer	0.00315	0.0221	CcSEcCtD
Methylergometrine—HTR2C—spinal cord—brain cancer	0.00311	0.00585	CbGeAlD
Methylergometrine—Thrombophlebitis—Temozolomide—brain cancer	0.00304	0.0214	CcSEcCtD
Methylergometrine—Hallucination—Procarbazine—brain cancer	0.003	0.021	CcSEcCtD
Methylergometrine—Nasal congestion—Temozolomide—brain cancer	0.00289	0.0203	CcSEcCtD
Methylergometrine—HTR2C—head—brain cancer	0.00276	0.0052	CbGeAlD
Methylergometrine—HTR2B—head—brain cancer	0.00259	0.00488	CbGeAlD
Methylergometrine—DRD1—brain—brain cancer	0.00258	0.00485	CbGeAlD
Methylergometrine—HTR2C—central nervous system—brain cancer	0.00252	0.00474	CbGeAlD
Methylergometrine—HTR2A—brainstem—brain cancer	0.00251	0.00472	CbGeAlD
Methylergometrine—HTR2B—central nervous system—brain cancer	0.00237	0.00445	CbGeAlD
Methylergometrine—Hallucination—Hydroxyurea—brain cancer	0.00232	0.0163	CcSEcCtD
Methylergometrine—Convulsion—Procarbazine—brain cancer	0.00227	0.016	CcSEcCtD
Methylergometrine—Hypertension—Procarbazine—brain cancer	0.00226	0.0159	CcSEcCtD
Methylergometrine—HTR2A—telencephalon—brain cancer	0.00223	0.00419	CbGeAlD
Methylergometrine—Sweating increased—Temozolomide—brain cancer	0.00222	0.0156	CcSEcCtD
Methylergometrine—Vomiting—Lomustine—brain cancer	0.00214	0.015	CcSEcCtD
Methylergometrine—Tachycardia—Procarbazine—brain cancer	0.00209	0.0147	CcSEcCtD
Methylergometrine—Hyperhidrosis—Procarbazine—brain cancer	0.00207	0.0145	CcSEcCtD
Methylergometrine—Nausea—Lomustine—brain cancer	0.002	0.0141	CcSEcCtD
Methylergometrine—HTR2C—brain—brain cancer	0.002	0.00377	CbGeAlD
Methylergometrine—Hypotension—Procarbazine—brain cancer	0.002	0.014	CcSEcCtD
Methylergometrine—Paraesthesia—Procarbazine—brain cancer	0.00192	0.0135	CcSEcCtD
Methylergometrine—HTR2B—brain—brain cancer	0.00188	0.00354	CbGeAlD
Methylergometrine—Hallucination—Carmustine—brain cancer	0.00187	0.0132	CcSEcCtD
Methylergometrine—HTR2A—gonad—brain cancer	0.00186	0.00349	CbGeAlD
Methylergometrine—HTR2A—pituitary gland—brain cancer	0.00181	0.00341	CbGeAlD
Methylergometrine—Hallucination—Temozolomide—brain cancer	0.00181	0.0127	CcSEcCtD
Methylergometrine—Sweating increased—Etoposide—brain cancer	0.00177	0.0125	CcSEcCtD
Methylergometrine—Convulsion—Hydroxyurea—brain cancer	0.00176	0.0123	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Procarbazine—brain cancer	0.00175	0.0123	CcSEcCtD
Methylergometrine—HTR2A—medulla oblongata—brain cancer	0.00175	0.00329	CbGeAlD
Methylergometrine—Tinnitus—Temozolomide—brain cancer	0.0017	0.0119	CcSEcCtD
Methylergometrine—Abdominal pain—Procarbazine—brain cancer	0.00169	0.0119	CcSEcCtD
Methylergometrine—Cardiac disorder—Temozolomide—brain cancer	0.00169	0.0119	CcSEcCtD
Methylergometrine—Nervous system disorder—Hydroxyurea—brain cancer	0.00162	0.0114	CcSEcCtD
Methylergometrine—HTR2A—midbrain—brain cancer	0.0016	0.00301	CbGeAlD
Methylergometrine—HTR2A—spinal cord—brain cancer	0.00156	0.00293	CbGeAlD
Methylergometrine—Dyspnoea—Hydroxyurea—brain cancer	0.00148	0.0104	CcSEcCtD
Methylergometrine—Diarrhoea—Procarbazine—brain cancer	0.00146	0.0103	CcSEcCtD
Methylergometrine—Convulsion—Carmustine—brain cancer	0.00142	0.00998	CcSEcCtD
Methylergometrine—Hypertension—Carmustine—brain cancer	0.00142	0.00995	CcSEcCtD
Methylergometrine—Dizziness—Procarbazine—brain cancer	0.00141	0.00994	CcSEcCtD
Methylergometrine—HTR2A—endocrine gland—brain cancer	0.0014	0.00264	CbGeAlD
Methylergometrine—Palpitations—Temozolomide—brain cancer	0.0014	0.00984	CcSEcCtD
Methylergometrine—Chest pain—Carmustine—brain cancer	0.0014	0.00981	CcSEcCtD
Methylergometrine—HTR2A—head—brain cancer	0.00139	0.00261	CbGeAlD
Methylergometrine—Convulsion—Temozolomide—brain cancer	0.00137	0.00964	CcSEcCtD
Methylergometrine—Hypertension—Temozolomide—brain cancer	0.00137	0.00961	CcSEcCtD
Methylergometrine—Vomiting—Procarbazine—brain cancer	0.00136	0.00955	CcSEcCtD
Methylergometrine—Cardiac disorder—Etoposide—brain cancer	0.00135	0.0095	CcSEcCtD
Methylergometrine—Rash—Procarbazine—brain cancer	0.00135	0.00947	CcSEcCtD
Methylergometrine—Dermatitis—Procarbazine—brain cancer	0.00135	0.00947	CcSEcCtD
Methylergometrine—Headache—Procarbazine—brain cancer	0.00134	0.00941	CcSEcCtD
Methylergometrine—Tachycardia—Carmustine—brain cancer	0.00131	0.00918	CcSEcCtD
Methylergometrine—CYP3A4—endocrine gland—brain cancer	0.0013	0.00244	CbGeAlD
Methylergometrine—Anaphylactic shock—Temozolomide—brain cancer	0.00129	0.00908	CcSEcCtD
Methylergometrine—Nausea—Procarbazine—brain cancer	0.00127	0.00893	CcSEcCtD
Methylergometrine—Nervous system disorder—Temozolomide—brain cancer	0.00127	0.00891	CcSEcCtD
Methylergometrine—HTR2A—central nervous system—brain cancer	0.00126	0.00238	CbGeAlD
Methylergometrine—Hypotension—Carmustine—brain cancer	0.00125	0.00878	CcSEcCtD
Methylergometrine—Hyperhidrosis—Temozolomide—brain cancer	0.00125	0.00878	CcSEcCtD
Methylergometrine—HTR2A—cerebellum—brain cancer	0.00124	0.00233	CbGeAlD
Methylergometrine—Muscle spasms—Etoposide—brain cancer	0.00122	0.00856	CcSEcCtD
Methylergometrine—Paraesthesia—Carmustine—brain cancer	0.0012	0.00844	CcSEcCtD
Methylergometrine—Dyspnoea—Carmustine—brain cancer	0.00119	0.00838	CcSEcCtD
Methylergometrine—CYP3A4—central nervous system—brain cancer	0.00117	0.0022	CbGeAlD
Methylergometrine—Paraesthesia—Temozolomide—brain cancer	0.00116	0.00816	CcSEcCtD
Methylergometrine—Dyspnoea—Temozolomide—brain cancer	0.00115	0.0081	CcSEcCtD
Methylergometrine—Diarrhoea—Hydroxyurea—brain cancer	0.00113	0.00796	CcSEcCtD
Methylergometrine—Convulsion—Etoposide—brain cancer	0.0011	0.00772	CcSEcCtD
Methylergometrine—Hypertension—Etoposide—brain cancer	0.0011	0.00769	CcSEcCtD
Methylergometrine—Dizziness—Hydroxyurea—brain cancer	0.0011	0.00769	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Carmustine—brain cancer	0.00109	0.00769	CcSEcCtD
Methylergometrine—Chest pain—Etoposide—brain cancer	0.00108	0.00758	CcSEcCtD
Methylergometrine—Abdominal pain—Carmustine—brain cancer	0.00106	0.00743	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Temozolomide—brain cancer	0.00106	0.00743	CcSEcCtD
Methylergometrine—Vomiting—Hydroxyurea—brain cancer	0.00105	0.00739	CcSEcCtD
Methylergometrine—Rash—Hydroxyurea—brain cancer	0.00104	0.00733	CcSEcCtD
Methylergometrine—Dermatitis—Hydroxyurea—brain cancer	0.00104	0.00733	CcSEcCtD
Methylergometrine—Headache—Hydroxyurea—brain cancer	0.00104	0.00729	CcSEcCtD
Methylergometrine—Anaphylactic shock—Etoposide—brain cancer	0.00104	0.00727	CcSEcCtD
Methylergometrine—Abdominal pain—Temozolomide—brain cancer	0.00102	0.00718	CcSEcCtD
Methylergometrine—Tachycardia—Etoposide—brain cancer	0.00101	0.0071	CcSEcCtD
Methylergometrine—HTR2A—brain—brain cancer	0.001	0.00189	CbGeAlD
Methylergometrine—Hyperhidrosis—Etoposide—brain cancer	0.001	0.00703	CcSEcCtD
Methylergometrine—Nausea—Hydroxyurea—brain cancer	0.000984	0.00691	CcSEcCtD
Methylergometrine—Hypotension—Etoposide—brain cancer	0.000967	0.00679	CcSEcCtD
Methylergometrine—Paraesthesia—Etoposide—brain cancer	0.00093	0.00653	CcSEcCtD
Methylergometrine—Dyspnoea—Etoposide—brain cancer	0.000923	0.00648	CcSEcCtD
Methylergometrine—Diarrhoea—Carmustine—brain cancer	0.000916	0.00643	CcSEcCtD
Methylergometrine—Dizziness—Carmustine—brain cancer	0.000885	0.00622	CcSEcCtD
Methylergometrine—Diarrhoea—Temozolomide—brain cancer	0.000885	0.00622	CcSEcCtD
Methylergometrine—Dizziness—Temozolomide—brain cancer	0.000855	0.00601	CcSEcCtD
Methylergometrine—Vomiting—Carmustine—brain cancer	0.000851	0.00598	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Etoposide—brain cancer	0.000846	0.00594	CcSEcCtD
Methylergometrine—Rash—Carmustine—brain cancer	0.000844	0.00593	CcSEcCtD
Methylergometrine—Dermatitis—Carmustine—brain cancer	0.000843	0.00592	CcSEcCtD
Methylergometrine—Headache—Carmustine—brain cancer	0.000839	0.00589	CcSEcCtD
Methylergometrine—Vomiting—Temozolomide—brain cancer	0.000823	0.00578	CcSEcCtD
Methylergometrine—Abdominal pain—Etoposide—brain cancer	0.000818	0.00575	CcSEcCtD
Methylergometrine—Rash—Temozolomide—brain cancer	0.000816	0.00573	CcSEcCtD
Methylergometrine—Dermatitis—Temozolomide—brain cancer	0.000815	0.00572	CcSEcCtD
Methylergometrine—Headache—Temozolomide—brain cancer	0.00081	0.00569	CcSEcCtD
Methylergometrine—Nausea—Carmustine—brain cancer	0.000795	0.00558	CcSEcCtD
Methylergometrine—Nausea—Temozolomide—brain cancer	0.000768	0.0054	CcSEcCtD
Methylergometrine—Diarrhoea—Etoposide—brain cancer	0.000708	0.00497	CcSEcCtD
Methylergometrine—Dizziness—Etoposide—brain cancer	0.000685	0.00481	CcSEcCtD
Methylergometrine—Vomiting—Etoposide—brain cancer	0.000658	0.00462	CcSEcCtD
Methylergometrine—Rash—Etoposide—brain cancer	0.000653	0.00458	CcSEcCtD
Methylergometrine—Dermatitis—Etoposide—brain cancer	0.000652	0.00458	CcSEcCtD
Methylergometrine—Headache—Etoposide—brain cancer	0.000649	0.00455	CcSEcCtD
Methylergometrine—Nausea—Etoposide—brain cancer	0.000615	0.00432	CcSEcCtD
Methylergometrine—HTR1F—Signaling Pathways—HEY1—brain cancer	1.1e-05	0.00234	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—GFAP—brain cancer	1.09e-05	0.00232	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—DLL1—brain cancer	1.08e-05	0.00229	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—ABR—brain cancer	1.07e-05	0.00228	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—VAV1—brain cancer	1.06e-05	0.00225	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PTCH2—brain cancer	1.05e-05	0.00222	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—HEY1—brain cancer	1.04e-05	0.0022	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—DLL1—brain cancer	1.02e-05	0.00216	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—HES5—brain cancer	1.01e-05	0.00215	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PTCH2—brain cancer	9.87e-06	0.0021	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—STRADA—brain cancer	9.84e-06	0.00209	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—ABR—brain cancer	9.74e-06	0.00207	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—TRPC6—brain cancer	9.69e-06	0.00206	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—DTX2—brain cancer	9.68e-06	0.00206	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—HES5—brain cancer	9.56e-06	0.00203	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—STRADA—brain cancer	9.28e-06	0.00197	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—SHH—brain cancer	9.17e-06	0.00195	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—TRPC6—brain cancer	9.14e-06	0.00194	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—SHH—brain cancer	9.13e-06	0.00194	CbGpPWpGaD
Methylergometrine—HTR2A—SIDS Susceptibility Pathways—CTNNB1—brain cancer	8.9e-06	0.00189	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—TRPC6—brain cancer	8.84e-06	0.00188	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—TRPC6—brain cancer	8.8e-06	0.00187	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—PTCH1—brain cancer	8.69e-06	0.00185	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—SMO—brain cancer	8.69e-06	0.00185	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—SMO—brain cancer	8.65e-06	0.00184	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—PTCH1—brain cancer	8.65e-06	0.00184	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—SHH—brain cancer	8.65e-06	0.00184	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—SHH—brain cancer	8.61e-06	0.00183	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PTCH2—brain cancer	8.44e-06	0.00179	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—TRPC6—brain cancer	8.34e-06	0.00177	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—TRPC6—brain cancer	8.3e-06	0.00176	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—ABR—brain cancer	8.21e-06	0.00175	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—PTCH1—brain cancer	8.2e-06	0.00174	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—SMO—brain cancer	8.2e-06	0.00174	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—HES5—brain cancer	8.18e-06	0.00174	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—PTCH1—brain cancer	8.16e-06	0.00173	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—SMO—brain cancer	8.16e-06	0.00173	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—STRADA—brain cancer	7.94e-06	0.00169	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—GLI2—brain cancer	7.93e-06	0.00169	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—PIK3CG—brain cancer	7.84e-06	0.00167	CbGpPWpGaD
Methylergometrine—HTR2A—SIDS Susceptibility Pathways—VEGFA—brain cancer	7.84e-06	0.00167	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—TRPC6—brain cancer	7.82e-06	0.00166	CbGpPWpGaD
Methylergometrine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	7.79e-06	0.00165	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—ABR—brain cancer	7.75e-06	0.00165	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—GLI2—brain cancer	7.48e-06	0.00159	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—GLI1—brain cancer	7.46e-06	0.00158	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—PIK3CG—brain cancer	7.39e-06	0.00157	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—SHH—brain cancer	7.36e-06	0.00156	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PTCH2—brain cancer	7.33e-06	0.00156	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—VAV1—brain cancer	7.26e-06	0.00154	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—PIK3CG—brain cancer	7.12e-06	0.00151	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—HES5—brain cancer	7.1e-06	0.00151	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—TRPC6—brain cancer	7.1e-06	0.00151	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—SUFU—brain cancer	7.07e-06	0.0015	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—GLI1—brain cancer	7.03e-06	0.00149	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—PTCH1—brain cancer	6.98e-06	0.00148	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—SMO—brain cancer	6.98e-06	0.00148	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—NOTCH2—brain cancer	6.95e-06	0.00148	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—STRADA—brain cancer	6.89e-06	0.00147	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—VAV1—brain cancer	6.85e-06	0.00146	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—GFAP—brain cancer	6.82e-06	0.00145	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—TRPC6—brain cancer	6.79e-06	0.00144	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—PIK3CG—brain cancer	6.72e-06	0.00143	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SUFU—brain cancer	6.67e-06	0.00142	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—ABR—brain cancer	6.63e-06	0.00141	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—VAV1—brain cancer	6.62e-06	0.00141	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—VAV1—brain cancer	6.59e-06	0.0014	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—NOTCH2—brain cancer	6.55e-06	0.00139	CbGpPWpGaD
Methylergometrine—DRD1—Circadian rythm related genes—TP53—brain cancer	6.51e-06	0.00138	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—HEY1—brain cancer	6.47e-06	0.00137	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—GFAP—brain cancer	6.43e-06	0.00137	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—GLI2—brain cancer	6.4e-06	0.00136	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—SHH—brain cancer	6.39e-06	0.00136	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—DLL1—brain cancer	6.34e-06	0.00135	CbGpPWpGaD
Methylergometrine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	6.28e-06	0.00134	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—VAV1—brain cancer	6.25e-06	0.00133	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—VAV1—brain cancer	6.22e-06	0.00132	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—TRPC6—brain cancer	6.17e-06	0.00131	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—HEY1—brain cancer	6.1e-06	0.0013	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—SMO—brain cancer	6.06e-06	0.00129	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PTCH1—brain cancer	6.06e-06	0.00129	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—GLI1—brain cancer	6.02e-06	0.00128	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—DLL1—brain cancer	5.98e-06	0.00127	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—VAV1—brain cancer	5.86e-06	0.00125	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ABR—brain cancer	5.75e-06	0.00122	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SUFU—brain cancer	5.7e-06	0.00121	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—HES1—brain cancer	5.7e-06	0.00121	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—GLI2—brain cancer	5.56e-06	0.00118	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—IL2—brain cancer	5.52e-06	0.00117	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—GFAP—brain cancer	5.5e-06	0.00117	CbGpPWpGaD
Methylergometrine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	5.46e-06	0.00116	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—PDGFRA—brain cancer	5.42e-06	0.00115	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—SHH—brain cancer	5.39e-06	0.00115	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—HES1—brain cancer	5.37e-06	0.00114	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—VAV1—brain cancer	5.32e-06	0.00113	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—SPP1—brain cancer	5.26e-06	0.00112	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—GLI1—brain cancer	5.22e-06	0.00111	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—HEY1—brain cancer	5.22e-06	0.00111	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—IL2—brain cancer	5.2e-06	0.00111	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—TRPC6—brain cancer	5.2e-06	0.0011	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—PDGFRA—brain cancer	5.12e-06	0.00109	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—DLL1—brain cancer	5.12e-06	0.00109	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PTCH1—brain cancer	5.11e-06	0.00109	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—SMO—brain cancer	5.11e-06	0.00109	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—VAV1—brain cancer	5.09e-06	0.00108	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SHH—brain cancer	5.08e-06	0.00108	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—IL2—brain cancer	5.01e-06	0.00106	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—SPP1—brain cancer	4.97e-06	0.00106	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SUFU—brain cancer	4.95e-06	0.00105	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—TRPC6—brain cancer	4.9e-06	0.00104	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PTCH1—brain cancer	4.82e-06	0.00102	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SMO—brain cancer	4.82e-06	0.00102	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—GFAP—brain cancer	4.78e-06	0.00102	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—IRS2—brain cancer	4.76e-06	0.00101	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—IL2—brain cancer	4.73e-06	0.001	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—VAV1—brain cancer	4.62e-06	0.000982	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—PIK3CG—brain cancer	4.61e-06	0.00098	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—HEY1—brain cancer	4.53e-06	0.000963	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—IRS2—brain cancer	4.49e-06	0.000955	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—DLL1—brain cancer	4.44e-06	0.000944	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SHH—brain cancer	4.35e-06	0.000924	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—PIK3CG—brain cancer	4.35e-06	0.000924	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—APC—brain cancer	4.21e-06	0.000894	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—PIK3CG—brain cancer	4.21e-06	0.000894	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TRPC6—brain cancer	4.19e-06	0.000891	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—PIK3CG—brain cancer	4.19e-06	0.00089	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PTCH1—brain cancer	4.12e-06	0.000876	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SMO—brain cancer	4.12e-06	0.000876	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NOTCH2—brain cancer	4.09e-06	0.000868	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—APC—brain cancer	3.97e-06	0.000843	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—PIK3CG—brain cancer	3.97e-06	0.000843	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—PIK3CG—brain cancer	3.95e-06	0.000839	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—VAV1—brain cancer	3.9e-06	0.000828	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NOTCH2—brain cancer	3.85e-06	0.000819	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—EGFR—brain cancer	3.83e-06	0.000814	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SHH—brain cancer	3.78e-06	0.000803	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—PIK3CG—brain cancer	3.72e-06	0.000791	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—VAV1—brain cancer	3.67e-06	0.000781	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TRPC6—brain cancer	3.64e-06	0.000774	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—EGFR—brain cancer	3.61e-06	0.000768	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SMO—brain cancer	3.58e-06	0.000761	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PTCH1—brain cancer	3.58e-06	0.000761	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—PIK3CG—brain cancer	3.38e-06	0.000718	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—HES1—brain cancer	3.35e-06	0.000712	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NOTCH2—brain cancer	3.3e-06	0.000701	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—RELA—brain cancer	3.29e-06	0.000698	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—ERBB2—brain cancer	3.27e-06	0.000694	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—IL2—brain cancer	3.24e-06	0.00069	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—PIK3CG—brain cancer	3.23e-06	0.000686	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PDGFRA—brain cancer	3.19e-06	0.000678	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—HES1—brain cancer	3.16e-06	0.000671	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—VAV1—brain cancer	3.14e-06	0.000668	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—RELA—brain cancer	3.1e-06	0.000659	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—SPP1—brain cancer	3.1e-06	0.000658	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—ERBB2—brain cancer	3.08e-06	0.000655	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—IL2—brain cancer	3.06e-06	0.00065	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP2C9—brain cancer	3.03e-06	0.000644	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PDGFRA—brain cancer	3.01e-06	0.000639	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—IL2—brain cancer	2.96e-06	0.000629	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—IL2—brain cancer	2.95e-06	0.000626	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PIK3CG—brain cancer	2.93e-06	0.000623	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SPP1—brain cancer	2.92e-06	0.000621	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CCND1—brain cancer	2.88e-06	0.000613	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NOTCH2—brain cancer	2.86e-06	0.000608	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CTNNB1—brain cancer	2.86e-06	0.000607	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IRS2—brain cancer	2.8e-06	0.000595	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—IL2—brain cancer	2.79e-06	0.000593	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—IL2—brain cancer	2.78e-06	0.000591	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—VAV1—brain cancer	2.73e-06	0.00058	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CCND1—brain cancer	2.72e-06	0.000578	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—HES1—brain cancer	2.7e-06	0.000574	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CTNNB1—brain cancer	2.69e-06	0.000573	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IRS2—brain cancer	2.64e-06	0.000561	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—IL2—brain cancer	2.62e-06	0.000556	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—BSG—brain cancer	2.58e-06	0.000547	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PDGFRA—brain cancer	2.57e-06	0.000547	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—VEGFA—brain cancer	2.51e-06	0.000534	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SPP1—brain cancer	2.5e-06	0.000531	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—STAT3—brain cancer	2.49e-06	0.000529	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CG—brain cancer	2.47e-06	0.000526	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—APC—brain cancer	2.47e-06	0.000526	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—IL2—brain cancer	2.38e-06	0.000505	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—VEGFA—brain cancer	2.37e-06	0.000504	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—STAT3—brain cancer	2.35e-06	0.000499	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—HES1—brain cancer	2.35e-06	0.000499	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—APC—brain cancer	2.33e-06	0.000496	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CG—brain cancer	2.33e-06	0.000496	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—MYC—brain cancer	2.31e-06	0.000492	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—IL2—brain cancer	2.27e-06	0.000483	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—EGFR—brain cancer	2.26e-06	0.000481	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IRS2—brain cancer	2.26e-06	0.00048	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—EGFR—brain cancer	2.25e-06	0.000479	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PDGFRA—brain cancer	2.23e-06	0.000475	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—IDH1—brain cancer	2.22e-06	0.000471	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—MYC—brain cancer	2.18e-06	0.000464	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SPP1—brain cancer	2.17e-06	0.000461	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—EGFR—brain cancer	2.13e-06	0.000454	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—EGFR—brain cancer	2.13e-06	0.000452	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—IL2—brain cancer	2.06e-06	0.000439	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CG—brain cancer	2e-06	0.000424	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—APC—brain cancer	2e-06	0.000424	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IRS2—brain cancer	1.96e-06	0.000417	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—RELA—brain cancer	1.93e-06	0.000411	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—ERBB2—brain cancer	1.92e-06	0.000408	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—TP53—brain cancer	1.9e-06	0.000404	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—RELA—brain cancer	1.82e-06	0.000387	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—EGFR—brain cancer	1.82e-06	0.000386	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—ERBB2—brain cancer	1.81e-06	0.000385	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—TP53—brain cancer	1.79e-06	0.000381	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ENO2—brain cancer	1.75e-06	0.000372	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IL2—brain cancer	1.74e-06	0.00037	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—APC—brain cancer	1.73e-06	0.000368	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CG—brain cancer	1.73e-06	0.000368	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCND1—brain cancer	1.7e-06	0.000361	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CTNNB1—brain cancer	1.68e-06	0.000357	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IL2—brain cancer	1.64e-06	0.000349	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCND1—brain cancer	1.6e-06	0.00034	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CTNNB1—brain cancer	1.58e-06	0.000337	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—EGFR—brain cancer	1.58e-06	0.000336	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—RELA—brain cancer	1.56e-06	0.000331	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—ERBB2—brain cancer	1.55e-06	0.000329	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—VEGFA—brain cancer	1.48e-06	0.000314	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—STAT3—brain cancer	1.46e-06	0.000311	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IL2—brain cancer	1.4e-06	0.000298	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—VEGFA—brain cancer	1.4e-06	0.000296	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—STAT3—brain cancer	1.38e-06	0.000294	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCND1—brain cancer	1.37e-06	0.000291	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MYC—brain cancer	1.36e-06	0.000289	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CTNNB1—brain cancer	1.36e-06	0.000288	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—RELA—brain cancer	1.35e-06	0.000288	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ERBB2—brain cancer	1.35e-06	0.000286	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—EGFR—brain cancer	1.33e-06	0.000283	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MYC—brain cancer	1.28e-06	0.000273	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—EGFR—brain cancer	1.26e-06	0.000267	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IL2—brain cancer	1.22e-06	0.000259	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—VEGFA—brain cancer	1.19e-06	0.000254	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCND1—brain cancer	1.19e-06	0.000253	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—STAT3—brain cancer	1.18e-06	0.000251	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CTNNB1—brain cancer	1.18e-06	0.00025	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—TP53—brain cancer	1.12e-06	0.000238	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MYC—brain cancer	1.1e-06	0.000233	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—EGFR—brain cancer	1.07e-06	0.000228	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—TP53—brain cancer	1.05e-06	0.000224	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—VEGFA—brain cancer	1.04e-06	0.00022	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—STAT3—brain cancer	1.03e-06	0.000218	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MYC—brain cancer	9.54e-07	0.000203	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—EGFR—brain cancer	9.33e-07	0.000198	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TP53—brain cancer	9.02e-07	0.000192	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CG—brain cancer	8.03e-07	0.000171	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TP53—brain cancer	7.83e-07	0.000166	CbGpPWpGaD
